Who we are and what we do
Etubics Corporation is a Seattle based biopharmaceutical company developing "next generation" vector vaccines to immunize or treat large worldwide populations having difficult to treat diseases such as select cancers, influenza viruses, HIV, malaria and hepatitis C virus. Etubics patent-protected pharmaceuticals, called adenovirus vectors, are safer, more effective, more versatile and easier to produce than competing products. They can also be utilized to re-immunize a vaccinee, solving a current challenge in the industry. Etubics was established by Dr. Frank R. Jones and is currently engaged in research, development and commercialization of its proprietary and novel adenovirus vector vaccine products.
Our Mission,
To develop "next generation" vector vaccine platforms to immunize and alleviate large worldwide populations from difficult to treat diseases such as certain cancers, influenza viruses, HIV and malaria.